Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I open label study to determine safety, tolerability and pharmacokinetics of single and repeated doses of F351

Trial Profile

Phase I open label study to determine safety, tolerability and pharmacokinetics of single and repeated doses of F351

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Hydronidone (Primary)
  • Indications Hepatic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 24 Apr 2018 According to a GNI media release, this trial is expected to be completed by the second half of 2018.
    • 24 Apr 2018 According to a GNI media release, first patient has been dosed.
    • 24 Apr 2018 Status changed from planning to recruiting, according to a GNI media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top